PDO MAX INC, a medical device provider for medical aesthetic needs in the United States and Canadian markets, has received 510(k) approval from the US Food and Drug Administration (FDA) for its brand of PDO (polydioxanone) absorbable threads in cannula, it was reported on Friday.
PDO threads are utilised in aesthetic medicine and are a sterile, biodegradable, monofilament synthetic composed polymer. The approval is for both the PDO threads and cannula integrated into one device, unlike many of the other providers in the market.
Juliana Ucchino, vice president of Operations for PDO Max Inc, said, 'We are dedicated to bringing our aesthetic medical professionals, true peace of mind with our FDA cleared PDO threads. PDO MAX threads, used alone, or in addition to the provider's preferred injectable product, greatly add to the ability of our medical professionals to deliver nonsurgical, minimally invasive total facial aesthetics solutions.'
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval